Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

Abstract The androgen receptor inhibitor enzalutamide is one of the principal treatments for metastatic prostate cancer. Most patients respond. However, a subset is primary refractory. Seeking to understand enzalutamide extreme non-response (ENR), we analyzed RNA-sequencing in biopsies from men trea...

Descripció completa

Dades bibliogràfiques

Autors principals:	Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A. Yates, Chao Zhang, Eva Rodansky, Dhruv Khokhani, Diana Flores, Zhi Duan, Yi Zhang, Shaadi Tabatabaei, Rachel Slottke, Shangyuan Ye, Primo Lara, Adam Foye, Charles J. Ryan, David A. Quigley, Jiaoti Huang, Rahul Aggarwal, Robert E. Reiter, Max S. Wicha, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Owen N. Witte, Joshua M. Stuart, George V. Thomas, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-07-01
Col·lecció:	npj Precision Oncology
Accés en línia:	https://doi.org/10.1038/s41698-025-01002-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!